Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluocinolone acetonide
Drug ID BADD_D00924
Description Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity.[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.[T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
Marketing Status Prescription; Discontinued
ATC Code C05AA10; D07AC04; S01BA15; S02BA08
DrugBank ID DB00591
KEGG ID D01825
MeSH ID D005446
PubChem ID 6215
TTD Drug ID D02QJH
NDC Product Code 64980-331; 63629-8655; 51927-0150; 68462-185; 0299-5500; 46439-8709; 64980-330; 51672-1365; 10135-670; 43538-911; 70752-159; 68791-101; 24208-416; 65162-704; 53183-0261; 49452-3156; 68462-591; 65162-703; 43538-900; 0168-0064; 71879-136; 65162-702; 43538-920; 71161-134; 0713-0709; 45802-887; 68791-102; 45802-485; 0395-8243; 43386-069; 43538-910; 71428-002; 70752-158; 0713-0223; 76420-163; 45802-009; 43538-921; 39328-079; 70752-156; 43538-901; 51672-1357; 68611-190; 0713-0224; 68791-103; 63629-8656; 51672-1356; 38779-0022; 68462-590
Synonyms Fluocinolone Acetonide | Acetonide, Fluocinolone | Fluortriamcinolone Acetonide | Acetonide, Fluortriamcinolone | Flurosyn | Jellin | Jellisoft | Synalar | Synalar-HP | Synalar HP | Synemol | Synamol | Alvadermo | Capex | Co-Fluocin | Co Fluocin | Cortiespec | Derma-Smooth FS | Derma Smooth FS | Flucinar | Fluocid | Fluodermo | Fluonid | Fluotrex | Flusolgen | Gelidina
Chemical Information
Molecular Formula C24H30F2O6
CAS Registry Number 67-73-2
SMILES CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abscess11.01.08.001--Not Available
Alopecia23.02.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.001532%
Angle closure glaucoma06.03.01.0010.001532%Not Available
Arthralgia15.01.02.001--
Back pain15.03.04.005--
Blepharitis06.04.04.001; 23.03.04.012--Not Available
Blindness06.02.02.001; 17.17.01.0030.005361%Not Available
Body temperature increased13.15.01.001--Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cataract06.06.01.0010.004595%
Cataract subcapsular06.06.01.002--Not Available
Choroidal detachment06.09.01.003; 12.01.04.006--Not Available
Condition aggravated08.01.03.004--Not Available
Conjunctival haemorrhage06.07.01.001; 24.07.05.001--Not Available
Conjunctival oedema06.04.01.001--Not Available
Corneal oedema06.04.02.0010.009956%Not Available
Cough22.02.03.001--
Deafness neurosensory04.02.01.002; 17.04.07.001--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--Not Available
Device expulsion27.01.01.002--Not Available
Diabetic retinal oedema05.07.01.001; 06.04.06.001; 14.07.01.0010.002297%Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.0030.001532%Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages